Botox and Dysport: is there a dose conversion ratio in dermatology and aesthetic medicine?

@article{Karsai2010BotoxAD,
  title={Botox and Dysport: is there a dose conversion ratio in dermatology and aesthetic medicine?},
  author={Syrus Karsai and Christian Raulin},
  journal={Journal of the American Academy of Dermatology},
  year={2010},
  volume={62 2},
  pages={346-7}
}
To the Editor: The use of botulinum neurotoxin A is the most frequent intervention in aesthetic medicine. Sales of the two main preparations—Botox (Allergan Inc, Irvine, CA) and Dysport (Ipsen Ltd, Slough, Berkshire, UK)—amounted to USD $1 billion in 2007, and the trend is still growing. Even after 15 years of clinical use, the unit equivalence between these two main botulinum neurotoxin A products is still a matter of discussion. Because of the different excipients used to dilute the test… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 15 references

A randomized double-blinded study of the effect of Dysport/Reloxin and Botox on forehead wrinkles and EMG activity

  • S Karsai, R Adrian, S Hammes, J Thimm, C. Raulin
  • Arch Dermatol 2007;143:1447-9
  • 2008

Equipotent doses of botulinum toxin type A products share same radius of action

  • DM Hexsel
  • Dermatol Times 2005;9:66
  • 2005

Similar Papers

Loading similar papers…